N-myc genomic content and DNA ploidy in stage IVS neuroblastoma.
DNA ploidy and N-myc genomic content were analyzed in a series of stage IVS neuroblastomas by flow cytometry and Southern blot hybridization, respectively. Of the 12 stage IVS neuroblastomas studied, nine were aneuploid (DNA index [DI] greater than 1), two were diploid (DI = 1), and one was not assessable for DNA content due to insufficient tumor material. N-myc gene amplification was present in two of 12 tumors. None of the aneuploid tumors exhibited N-myc amplification. Among the aneuploid neuroblastomas, the DIs were between 1.27 and 1.60, ie, in the near-triploid range. The follow-up from diagnosis ranged from 1 to 41 months (mean, 20 months). The nine neuroblastomas with near-triploid DNA content were free of disease at the end of the follow-up period. In contrast, a rapid and fatal tumor progression was observed for the three neuroblastomas with N-myc amplification and/or diploidy. Although involving only a limited series, these results strongly suggest that the combined analysis of DNA ploidy and N-myc genomic content could predict clinical outcome in stage IVS neuroblastoma and should help to identify patients for whom a more aggressive therapy is required.
Bourhis
J
J
Laboratory of Clinical and Molecular Pharmacology, Institut Gustave Roussy, Villejuif, France.
Dominici
C
C
McDowell
H
H
Raschella
G
G
Wilson
G
G
Castello
M A
MA
Plouvier
E
E
Lemerle
J
J
Riou
G
G
Bénard
J
J
D000782:Aneuploidy; D015139:Blotting, Southern; D004273:DNA, Neoplasm / Q000032:analysis / Q000235:genetics*; D005434:Flow Cytometry; D005500:Follow-Up Studies; D005784:Gene Amplification; D016259:Genes, myc; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D011003:Ploidies; D011379:Prognosis
D004273:DNA, Neoplasm